China National Pharmaceutical Group Corporation (Sinopharm)
Chinese state-owned pharmaceutical and biotechnology enterprise, serves as a holding company for multiple pharmaceutical subsidiaries; 100% owned by the Chinese central government.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1998
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- A WHO-supported cohort study of 1,230 Egyptian healthcare workers found COVID-19 vaccines demonstrated 68% effectiveness against symptomatic RT-PCR confirmed infections, though results were not statistically significant due to limited case numbers. - The study revealed that 99.8% of participants were seropositive for COVID-19 antibodies at enrollment, with all unvaccinated workers showing evidence of prior infection, highlighting widespread exposure in healthcare settings. - Healthcare workers with hybrid immunity (vaccination plus prior infection) showed enhanced protection with 89% vaccine effectiveness, while mRNA vaccines appeared superior to inactivated vaccines in preventing breakthrough infections. - Despite breakthrough infections occurring in 83.3% of positive cases among vaccinated workers, no hospitalizations or deaths were recorded, consistent with milder Omicron variant outcomes during the study period.
- Chengdu UCELLO Biotech's CD19-targeted allogeneic universal CAR-T therapy UC101 received FDA IND approval on January 11, 2025, marking a historic milestone as the first such product worldwide. - The therapy represents a significant advancement in CAR-T technology by utilizing allogeneic universal T cells rather than patient-specific autologous cells, potentially reducing manufacturing time and costs. - Challenge IM provided critical ultrafiltration technology and automated cross-flow filtration systems to support UC101's manufacturing processes, demonstrating the importance of specialized bioprocessing equipment in cell therapy development.
- Sinopharm's mpox vaccine candidate has been approved by China's drug regulator for clinical trials, joining other domestic candidates. - Preclinical studies suggest the Sinopharm vaccine is safe and effective, stimulating immune protection against mpox in animal models. - China reported its first domestic mpox case in June 2023 and has classified it as a Class B infectious disease. - Another mpox vaccine candidate from Sinopharm's Shanghai Institute of Biological Products received clinical trial approval in September.
- Sinopharm's mpox vaccine candidate, developed by the Shanghai Institute of Biological Products, has been approved for clinical trials in China. - The vaccine is a replication-deficient vaccine based on the Modified Vaccinia Ankara (MVA) strain, similar to the Jynneos vaccine. - Preclinical studies suggest the vaccine can generate good immune protection against the mpox virus in non-human primate models. - China has reported over 2,500 mpox cases and currently has no approved mpox vaccines, making this a significant step.
